Development of a Clonal and High-Yield Mammalian Cell Line for the Manufacturing of a Hyperactive Human DNase I with Extended Plasma Half-Life Using PASylation^® Technology

Keyphrases

• PASylation 100%
• Plasma Half-life 100%
• Mammalian Cell Lines 100%
• DNase 100%
• Neutrophil Extracellular Traps 40%
• Dornase Alfa 40%
• Immune Cells 20%
• Inflammation 20%
• Future Production 20%
• High Catalytic Activity 20%
• Downstream Process 20%
• Surrounding Environment 20%
• Therapeutic Approaches 20%
• Physicochemical Properties 20%
• Pharmacokinetic Profile 20%
• Polypeptide 20%
• Bioprocess 20%
• Protein Drug 20%
• Cell Release 20%
• Good Manufacturing Practice 20%
• Cystic Fibrosis 20%
• Slow Clearance 20%
• Genetic Fusion 20%
• Hydrodynamic Volume 20%
• Inflammatory State 20%
• Clot 20%
• Therapeutic Utility 20%
• DNase Activity 20%
• CHO-K1 20%
• Clinical Outcomes 20%
• Recombinant Form 20%
• Kidney Filtration 20%
• Inhaled Therapy 20%
• Pulmozyme 20%
• Granular Proteins 20%

Immunology and Microbiology

• Neutrophil Extracellular Traps 100%
• Cell Line 100%
• Plasma Half Life 100%
• Blood Plasma 50%
• Immunocompetent Cell 50%
• Preclinical Study 50%
• Glomerulus Filtration 50%
• Pharmacokinetics 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Deoxyribonuclease I 100%
• Dornase Alfa 75%
• Deoxyribonuclease 50%
• Preclinical Study 25%
• Good Manufacturing Practice 25%
• Polypeptide 25%
• Cystic Fibrosis 25%
• Inflammation 25%
• Pharmacokinetics 25%